Enekinragene inzadenovec is under clinical development by Pacira BioSciences and currently in Phase I for Osteoarthritis. According to GlobalData, Phase I drugs for Osteoarthritis does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Enekinragene inzadenovec LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Enekinragene inzadenovec overview
See Also:
Pacira BioSciences overview
Pacira BioSciences (Pacira), formerly Pacira Pharmaceuticals Inc, provides non-opioid pain management and regenerative health solutions. The company develops drugs based on its proprietary DepoFoam drug delivery technology. Its lead product candidate, Exparel (bupivacaine liposome injectable suspension) is an amide-type local anesthetic administered at the time of surgery to control pain and eliminate the use of opioids for acute postsurgical pain. Its other products include iovera, a non-opioid treatment intended to block pain, and relieve pain and symptoms related to osteoarthritis of the knee; among others. Its products are essentially used by hospitals, doctors and ambulatory surgery centers. It also sells products through co-promotion agreements and supply agreements with other pharmaceutical companies. The company has operations in the US and the UK. Pacira is headquartered in Tampa, Florida, the US.
For a complete picture of Enekinragene inzadenovec’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
